Novel Peptide-Drug Conjugate (PDC) Service
Inquiry
AI Cyclic Peptide Drug Design Background

Novel Peptide-Drug Conjugate (PDC) Service

Overview

Peptide-drug conjugates (PDCs) represent an emerging class of targeted therapeutics that combine the specificity of peptides with the potency of cytotoxic or modulatory payloads. By leveraging peptide-mediated targeted delivery, PDCs offer advantages over traditional antibody-drug conjugates (ADCs) including lower immunogenicity, better tissue penetration, and reduced manufacturing complexity. At CD ComputaBio, we provide an integrated AI-powered PDC design service that accelerates the development of next-generation targeted therapies from concept to candidate.

Figure 1. Novel Peptide-Drug Conjugate (PDC) Service.Figure 1. Novel Peptide-Drug Conjugate (PDC) Service.

Introduction to Novel Peptide-Drug Conjugate (PDC) Service

Peptide-drug conjugates consist of three key components: a targeting peptide that binds to a receptor overexpressed on disease cells, a chemical linker that controls payload release, and a therapeutic payload that exerts the desired biological effect. The design of effective PDCs requires careful optimization of each component and their interactions. We have built an integrated AI-powered platform dedicated to novel PDC design. Our system combines peptide discovery engines, linker design algorithms, payload selection tools, and conjugation chemistry planning within a unified workflow. This approach eliminates the trial-and-error inefficiency of traditional PDC development, enabling systematic optimization of targeting specificity, linker stability, and payload potency. Our team of peptide chemists, medicinal chemists, and conjugation scientists works alongside our AI platform to ensure that designed PDCs achieve the right balance of target selectivity, circulation stability, tumor penetration, and controlled payload release. The result: accelerated development timelines and improved probability of success for PDC therapeutics.

Application Scenarios

Our PDC design service supports a wide range of targeted therapeutic programs:

  • Oncology Targeted Therapy: Design PDCs that deliver cytotoxic payloads specifically to tumor cells overexpressing peptide receptors such as somatostatin receptors, integrins, or GPCRs, reducing systemic toxicity compared to conventional chemotherapy.
  • Inflammatory Disease Targeting: Develop PDCs that deliver anti-inflammatory payloads to disease-affected tissues, achieving local efficacy while minimizing systemic immunosuppression.
  • Fibrosis-Directed Treatment: Create PDCs that target activated fibroblasts or extracellular matrix components to deliver anti-fibrotic agents specifically to fibrotic lesions.
  • Intracellular Delivery Enhancement: Design cell-penetrating peptide (CPP)-based PDCs that facilitate delivery of otherwise impermeable payloads into target cells, expanding the druggable space for intracellular targets.
  • Dual-Targeting Strategies: Develop PDCs incorporating bispecific or multi-targeting peptide sequences to enhance selectivity for cells expressing multiple disease-associated markers.

Our Services

We offer a comprehensive suite of AI-powered PDC design and optimization services:

Targeting Peptide Discovery & Optimization

Our AI generative engine designs novel peptide sequences with high affinity and selectivity for your target receptor. We optimize for binding, stability, and manufacturability while minimizing off-target interactions.

Linker Design & Optimization

Custom design of cleavable or non-cleavable linkers optimized for the specific release mechanism required by your therapeutic application. Our platform predicts linker stability in circulation and payload release kinetics at the target site.

Payload Selection & Conjugation Planning

Expert guidance on payload selection including cytotoxic agents, anti-inflammatory compounds, or modulatory peptides. We plan optimal conjugation sites and chemistries to maintain payload activity and conjugation efficiency.

PDC Property Prediction & Optimization

Integrated prediction of PDC-specific properties including serum stability, aggregation tendency, target binding after conjugation, and pharmacokinetic behavior. Multi-parameter optimization balances all relevant attributes.

Synthetic Feasibility & Manufacturability Assessment

Early assessment of synthesis complexity, conjugation yield, and scale-up potential. Our platform identifies practical challenges before development commitment, reducing downstream risk.

Process of Novel Peptide-Drug Conjugate (PDC) Service

Our Novel Peptide-Drug Conjugate (PDC) Service process is designed for efficiency, accuracy, and compliance at every stage:

Target Definition & Requirements Analysis: We collaborate with you to define target biology, desired payload mechanism, release profile requirements, and development objectives. This foundation guides all subsequent design decisions.

Component Design & Optimization: Targeting peptides, linkers, and conjugation strategies are designed and optimized in parallel using our AI platform. Each component is refined independently before integration.

Integrated PDC Modeling: Optimized components are combined into complete PDC candidates. Our platform predicts overall properties including serum stability, target binding affinity after conjugation, and payload release kinetics.

Multi-Parameter Candidate Ranking: Candidates are evaluated across multiple dimensions including targeting specificity, stability, potency, safety, and synthetic feasibility. An integrated developability score supports objective selection.

Our Advantages

Holistic Three-Component Optimization

Unlike services that focus only on the peptide or only on conjugation chemistry, our platform simultaneously optimizes targeting peptide, linker, and payload as an integrated system. This holistic approach prevents suboptimal trade-offs where improving one component inadvertently compromises another, ensuring that the final PDC candidate achieves the best possible balance of targeting specificity, stability, and potency.

Cyclic & Linear Peptide Compatibility

Our platform supports both linear and cyclic peptide formats for targeting, enabling optimal design choices based on your specific target and application requirements. This flexibility allows us to select the peptide topology that best suits your target binding needs, metabolic stability requirements, and manufacturing constraints, rather than forcing a one-size-fits-all solution.

Accelerated Design-Build-Test Cycles

A: By integrating AI prediction with synthesis and testing workflows, we compress traditional PDC development timelines, enabling rapid iteration and faster progression to lead candidates. This efficiency means your program can explore more design hypotheses and converge on optimal candidates in weeks rather than months, providing a meaningful competitive advantage.

Frequently Asked Questions

Connect with Us Anytime!

Peptide-drug conjugates offer a compelling pathway to targeted therapeutics with the precision of biologics and the convenience of small molecules. By combining AI-driven design with deep expertise in peptide chemistry, linker technology, and conjugation science, CD ComputaBio provides a differentiated PDC development service that accelerates the path from concept to candidate. Whether you are targeting solid tumors, inflammatory diseases, or other indications, our integrated platform can help you design effective PDC therapeutics. Contact us to discuss how we can support your targeted drug discovery programs.

* For Research Use Only.
Related Services